Schank, T.E.; Forschner, A.; Sachse, M.M.; Dimitrakopoulou-Strauss, A.; Sachpekidis, C.; Stenzinger, A.; Volckmar, A.-L.; Enk, A.; Hassel, J.C.
Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival. Cancers 2021, 13, 2616.
https://doi.org/10.3390/cancers13112616
AMA Style
Schank TE, Forschner A, Sachse MM, Dimitrakopoulou-Strauss A, Sachpekidis C, Stenzinger A, Volckmar A-L, Enk A, Hassel JC.
Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival. Cancers. 2021; 13(11):2616.
https://doi.org/10.3390/cancers13112616
Chicago/Turabian Style
Schank, Timo E., Andrea Forschner, Michael Max Sachse, Antonia Dimitrakopoulou-Strauss, Christos Sachpekidis, Albrecht Stenzinger, Anna-Lena Volckmar, Alexander Enk, and Jessica C. Hassel.
2021. "Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival" Cancers 13, no. 11: 2616.
https://doi.org/10.3390/cancers13112616
APA Style
Schank, T. E., Forschner, A., Sachse, M. M., Dimitrakopoulou-Strauss, A., Sachpekidis, C., Stenzinger, A., Volckmar, A.-L., Enk, A., & Hassel, J. C.
(2021). Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival. Cancers, 13(11), 2616.
https://doi.org/10.3390/cancers13112616
